FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168986237> ?p ?o ?g. }

• W2168986237 endingPage "1039" @default.
• W2168986237 startingPage "1037" @default.
• W2168986237 abstract "While unfractionated heparin (UFH) + glycoprotein IIB/IIIA inhibitors (GPI) have been considered the ‘gold standard’ for preventing ischaemic complications during percutaneous coronary intervention (PCI), the quest for a safer (with respect to complications from bleeding) and equally effective (with respect to complications from ischaemia) anticoagulant led to the development of the direct thrombin inhibitor, bivalirudin. Bivalirudin has been tested in pivotal randomised trials1–7 of patients with stable angina, acute coronary syndrome (ACS) and ST-segment elevation myocardial infarction (STEMI). In these trials, bivalirudin consistently reduced complications from bleeding, with no difference in ischaemic events.1–7 In the HORIZONS-AMI trial of 3602 patients with STEMI who were undergoing primary PCI,2 ,3 bivalirudin was also associated with a 1.1% reduction in 30-day mortality,2 which was sustained at 1 and 3 years.3 Given these advantages, but the high costs of drug acquisition, the cost-effectiveness of bivalirudin have been of great interest to payers and hospitals.Prior economic evaluations of bivalirudin relative to UFH + GPI in the setting of non-emergent PCI (REPLACE-2) and ACS (ACUITY), from the US healthcare system, have demonstrated cost savings associated with bivalirudin.8 ,9 A cost-effective model from the UK perspective, that used data inputs from the ACUITY trial, also found bivalirudin to be cost effective (though not cost saving).10 However, until the present study10a no economic evaluation of bivalirudin in patients with STEMI undergoing primary PCI has appeared in the literature. In this edition of Heart , Schwenkglenks et al 10a present a model-based cost-effectiveness analysis from the UK perspective of bivalirudin versus UFH + GPI for patients with STEMI, who were undergoing primary PCI, based on results from HORIZONS-AMI. Using …" @default.
• W2168986237 created "2016-06-24" @default.
• W2168986237 creator A5054187061 @default.
• W2168986237 creator A5083685816 @default.
• W2168986237 date "2012-06-27" @default.
• W2168986237 modified "2023-09-26" @default.
• W2168986237 title "Understanding the cost-effectiveness of bivalirudin" @default.
• W2168986237 cites W165703145 @default.
• W2168986237 cites W1963589629 @default.
• W2168986237 cites W1976594290 @default.
• W2168986237 cites W1999619945 @default.
• W2168986237 cites W2024376801 @default.
• W2168986237 cites W2024639563 @default.
• W2168986237 cites W2030271409 @default.
• W2168986237 cites W2031533013 @default.
• W2168986237 cites W2055474976 @default.
• W2168986237 cites W2059136191 @default.
• W2168986237 cites W2073159589 @default.
• W2168986237 cites W2095231855 @default.
• W2168986237 cites W2102296549 @default.
• W2168986237 cites W2103428481 @default.
• W2168986237 cites W2103678369 @default.
• W2168986237 cites W2111298633 @default.
• W2168986237 cites W2121251309 @default.
• W2168986237 cites W2123026835 @default.
• W2168986237 cites W2127531097 @default.
• W2168986237 cites W2128715802 @default.
• W2168986237 cites W2135653600 @default.
• W2168986237 cites W2144358917 @default.
• W2168986237 cites W2147482806 @default.
• W2168986237 cites W2150086052 @default.
• W2168986237 cites W2156927593 @default.
• W2168986237 cites W2518943150 @default.
• W2168986237 cites W2887768525 @default.
• W2168986237 cites W3209376675 @default.
• W2168986237 cites W2070401210 @default.
• W2168986237 doi "https://doi.org/10.1136/heartjnl-2012-301649" @default.
• W2168986237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22739634" @default.
• W2168986237 hasPublicationYear "2012" @default.
• W2168986237 type Work @default.
• W2168986237 sameAs 2168986237 @default.
• W2168986237 citedByCount "2" @default.
• W2168986237 countsByYear W21689862372014 @default.
• W2168986237 countsByYear W21689862372019 @default.
• W2168986237 crossrefType "journal-article" @default.
• W2168986237 hasAuthorship W2168986237A5054187061 @default.
• W2168986237 hasAuthorship W2168986237A5083685816 @default.
• W2168986237 hasConcept C126322002 @default.
• W2168986237 hasConcept C177713679 @default.
• W2168986237 hasConcept C2777565915 @default.
• W2168986237 hasConcept C2780400711 @default.
• W2168986237 hasConcept C500558357 @default.
• W2168986237 hasConcept C71924100 @default.
• W2168986237 hasConceptScore W2168986237C126322002 @default.
• W2168986237 hasConceptScore W2168986237C177713679 @default.
• W2168986237 hasConceptScore W2168986237C2777565915 @default.
• W2168986237 hasConceptScore W2168986237C2780400711 @default.
• W2168986237 hasConceptScore W2168986237C500558357 @default.
• W2168986237 hasConceptScore W2168986237C71924100 @default.
• W2168986237 hasIssue "14" @default.
• W2168986237 hasLocation W21689862371 @default.
• W2168986237 hasLocation W21689862372 @default.
• W2168986237 hasOpenAccess W2168986237 @default.
• W2168986237 hasPrimaryLocation W21689862371 @default.
• W2168986237 hasRelatedWork W1964470549 @default.
• W2168986237 hasRelatedWork W1970371692 @default.
• W2168986237 hasRelatedWork W201942647 @default.
• W2168986237 hasRelatedWork W2025630420 @default.
• W2168986237 hasRelatedWork W2289214695 @default.
• W2168986237 hasRelatedWork W2748952813 @default.
• W2168986237 hasRelatedWork W2899084033 @default.
• W2168986237 hasRelatedWork W3135394311 @default.
• W2168986237 hasRelatedWork W4205367701 @default.
• W2168986237 hasRelatedWork W4252371801 @default.
• W2168986237 hasVolume "98" @default.
• W2168986237 isParatext "false" @default.
• W2168986237 isRetracted "false" @default.
• W2168986237 magId "2168986237" @default.
• W2168986237 workType "article" @default.